In a move to diversify its business, Australian biopharma CSL has agreed to acquire Vifor Pharma for $11.7 billion. The deal would give CSL—heavily dependent on vaccines and blood plasma ...
Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global specialty pharmaceutical company with leadership in iron deficiency, ...
Australian biotech giant CSL Ltd is in exclusive talks to buy Vifor Pharma in a A$10 billion ($7.10 billion) deal, the Australian newspaper reported on Thursday, sending the Swiss drugmaker's shares ...
ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results